GPIIbIIIaBlocker
GPIIbIIIa blockers are a class of antiplatelet medications that prevent blood clots from forming. They work by targeting a specific protein complex on the surface of platelets called the GPIIb/IIIa receptor. This receptor is crucial for platelet aggregation, the process by which platelets stick together to form a clot. By blocking this receptor, these drugs inhibit the final common pathway of platelet aggregation, regardless of the initial trigger.
These medications are typically administered intravenously in a hospital setting, most commonly during percutaneous coronary intervention
The primary indication for GPIIb/IIIa blockers is to reduce the risk of ischemic events in patients undergoing